Portfolio company
Orbits Oncology
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
Orbits Oncology develops an AI-powered image analysis platform for cancer organoid drug screening and therapy matching for biopharma companies and oncologists.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Oncosyne
This company develops patient-derived tumoroid drug screening platforms for pharmaceutical firms and oncologists to improve drug discovery and personalised cancer treatment.
Orakl Oncology
This company develops a predictive platform using patient tumor avatars and data to help pharmaceutical firms accelerate and de-risk cancer drug development.
Organo-ID
The company develops 3D organoid models and drug response tests for cancer patients and pharmaceutical researchers to improve personalised medicine and treatment efficacy.
Known Medicine
This company develops a platform using 3D cell culture and artificial intelligence to predict drug responses for oncologists and biopharmaceutical developers.
Pear Bio
The company develops a precision medicine platform using microfluidic chips and computer vision to predict cancer treatment efficacy for oncologists and pharmaceutical researchers.
PreComb
This company develops a precision oncology platform using patient-derived microtumour models and automated analysis to predict drug responses for biopharmaceutical firms and clinical institutions.
Orbit Genomics
This company develops AI-powered genomic tests for healthcare providers and patients to diagnose lung cancer and evaluate risks for chronic diseases.
Elephas Biosciences
This company develops a live tissue platform for predicting immunotherapy response to assist oncologists, researchers, and pharmaceutical developers in cancer treatment.